[1] Döhner H, Wei A H, Appelbaum F R, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022,140(12): 1345-1377.
[2] Daver N G, Iqbal S, Renard C, et al. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis[J]. J Hematol Oncol, 2023,16(1):19-32.
[3] Hunter A M,Sallman D A.Current status and new treatment approaches in TP53 mutated AML[J].Best Pract Res Clin Haematol,2019,32(2):134-144.
[4] 陈文敏, 刘 虹, 李玲娣, 等.TP53基因突变阳性成人急性髓系白血病患者初诊临床及分子遗传学特征分析[J] .中华血液学杂志, 2019,40 (6): 528-531.
[5] Loschi M, Fenaux P, Cluzeau T. How I treat TP53-mutated acute myeloid leukemia and myelodysplastic syndromes [J]. Cancers (Basel), 2022,14(18): 4519-4530.
[6] 张 莹, 胡晓霞, 高 磊, 等.伴TP53基因异常急性髓系白血病患者的临床特征及预后分析 [J] .中华血液学杂志,2019,40 (11): 932-938.
[7] 米瑞华, 郭 珍, 刘 雯, 等.伴TP53基因异常的急性白血病患者的临床特征和疗效分析 [J] . 中华医学遗传学杂志, 2021, 38(10) : 955-960.
[8] Dinardo C D, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1):7-17.
[9] Becker H, Pfeifer D, Ihorst G, et al. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia[J]. Ann Hematol, 2020, 99(7): 1551-1560.
[10] Chen S S, Sun Q, Cao L, et al.Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation [J].Chin Med J(Engl), 2020, 134(12):1477-1479.
[11] Daver N G,Vyas P, Kambhampati S, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results [J]. J Clin Oncol,2022:40(16):7020-7023.
[12] Sallman D A, Komrokji R S, DeZern A E, et al. Long term follow-up and combined phase 2 results of eprenetapopt(APR-246) and azacitidine(AZA) in patients with TP53 mutant myelodysplastic syndromes(MDS) and oligoblastic acute myeloid leukemia(AML) [J]. Blood, 2021,138(suppl 1): 246-248.
[13] Guillermo G M, Aaron D G, Eric S W, et al. Phase Ⅰ and expansion study of eprenetapopt (APR-246) in combination with venetoclax(VEN) and azacitidine(AZA) in TP53-mutant acute myeloid leukemia(AML) [J]. Blood, 2021,138(suppl 1): 3409-3413.
[14] Brunner A M,Esteve J,Porkka K,et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): updated results from a phase 1b study[J].Blood, 2020,136 (Suppl 1):1-2.
[15] Chen S, Wu J L, Liang Y, et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site[J]. Cancer Cell, 2021, 39(2): 225-239.
[16] Short N J, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia[J]. Blood Adv, 2020, 4(22):5681-5689.
[17] Xu J,Wang J,Hu Y,et al.Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity[J].Cell Death Dis,2014,5(3): e1108-e1116.
[18] Bernard E, Nannya Y, Hasserjian R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020,26(10): 1549-1556.